

March 2, 2022

Sumitomo Dainippon Pharma Co., Ltd.

**Sumitomo Dainippon Pharma Announces Changes in Executive Officers
Including Representative Director, Organizational Realignment and
Personnel Changes**

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced the following organizational realignment and personnel changes of directors and executive officers, including representative director.

I. Change in Representative Director (effective March 31, 2022)

(1) Reason

Hitoshi Odagiri, Representative Director, Executive Vice President, offered to resign as the representative director as of March 31, 2022.

(2) Retiring Representative Director

Name	New position	Current position
Hitoshi Odagiri	Member, Board of Directors	Representative Director, Executive Vice President

II. Changes in Executive Officers

(1) Promotions (effective April 1, 2022)

Senior Executive Officer

Atsuko Higuchi (currently Executive Officer)

Takuya Taguchi (currently Executive Officer)

(2) New Executive Officers (effective April 1, 2022)

Naoki Noguchi (currently Chairman, President & CEO, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.)

Tsutomu Nakagawa (currently Senior Director, Global Corporate Strategy)

(3) Changes in the positions assumed by Executive Officers (effective April 1, 2022)

Position as of April 1, 2022	Current position	Name
Representative Director, Executive Vice President Global Corporate Strategy; Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant	Representative Director, Executive Vice President Chief Scientific Officer Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant	Toru Kimura
Member, Board of Directors, Senior Executive Officer Cancer Research; Modality Research; Drug Research Division Head of Japan Business Unit	Member, Board of Directors, Senior Executive Officer Regulatory Affairs; Medical Information; Medical Affairs; Corporate Regulatory Compliance & Quality Assurance Division; Technology Research & Development Division; Manufacturing Division Executive Director, Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit	Yoshiharu Ikeda
Member, Board of Directors	Representative Director, Executive Vice President Sales & Marketing Division Executive Director, Sales & Marketing Division Senior Director, CNS Sales Department Head of Japan Business Unit	Hitoshi Odagiri
Senior Executive Officer Global Data Design Office; Legal Affairs; Intellectual Property; IT Management & Digital Transformation; Frontier Business Office	Senior Executive Officer Global Data Design Office; External Affairs; Legal Affairs; Intellectual Property; Corporate Secretariat; IT Management & Digital Transformation; Frontier Business Office	Hiroyuki Baba

Senior Executive Officer Global Business Development; International Business Management	Senior Executive Officer Global Corporate Strategy; Global Business Development; International Business Management	Shigeyuki Nishinaka
Senior Executive Officer Technology Research & Development Division; Manufacturing Division Deputy Head of Japan Business Unit	Senior Executive Officer Drug Research Division Senior Executive Research Director, Drug Research Division	Hideyuki Harada
Senior Executive Officer External Affairs; Corporate Secretariat; Human Resources	Executive Officer Corporate Governance; Corporate Communications; Human Resources	Atsuko Higuchi
Senior Executive Officer Sales & Marketing Division Executive Director, Sales & Marketing Division Deputy Head of Japan Business Unit	Executive Officer Deputy Executive Director, Sales & Marketing Division	Takuya Taguchi
Executive Officer Regulatory Affairs; Medical Information; Medical Affairs; Corporate Regulatory Compliance & Quality Assurance Executive Director, Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit	Executive Officer Drug Development Division Executive Director, Drug Development Division Deputy Executive Director, Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit	Koichi Kozuki
Executive Officer Senior Executive Research Director, Drug Research Division	Executive Officer Executive Research Director, Drug Research Division	Isao Shimizu
Executive Officer Drug Development Division Executive Director, Drug Development Division Executive Vice President and Chief	Executive Officer Executive Vice President and Chief Corporate Strategy Officer, Sunovion Pharmaceuticals Inc.	Yumi Sato

Corporate Strategy Officer, Sunovion Pharmaceuticals Inc.		
Executive Officer Corporate Governance; Corporate Communications Senior Director, Corporate Governance	Chairman, President & CEO, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.	Naoki Noguchi
Executive Officer Senior Director, Global Corporate Strategy	Senior Director, Global Corporate Strategy	Tsutomu Nakagawa
Executive Officer CEO, Sumitomo Pharma Oncology, Inc. Global Head of Oncology	Executive Officer CEO, Sumitomo Dainippon Pharma Oncology, Inc. Global Head of Oncology	Patricia S. Andrews

III. Organizational Realignment (effective April 1, 2022)

Corporate Departments

1. Oncology Strategy Unit is dissolved.
2. DSP Cancer Institute is renamed to Cancer Research Unit.
3. Modality Research Unit is created.
 - * Modality Research Unit is established for continuous development of drug discovery platforms based on diverse drug modalities, which leads to accelerate R&D process and improve R&D productivity and clinical success probability.

Sales & Marketing (Division)

1. Rare Diseases Office is created.
 - * We have signed a new alliance agreement with JCR Pharmaceuticals Co., Ltd. regarding the sales of recombinant Fabry disease therapeutic agents, and will start providing information to healthcare professionals from April 2022. Rare Diseases Office is established for ongoing contributions to the treatment of patients with Fabry disease.
2. Kobe Branch is integrated to Osaka Branch.

IV. Changes in Personnel (effective April 1, 2022)

Corporate Departments

Position as of April 1, 2022	Current position	Name
Senior Director, External Affairs	Director, External Affairs	Eiji Anzai
Senior Director, Human Resources	Senior Director, Corporate Governance	Masaki Yamamoto
Senior Director, Cancer Research Unit	Senior Director, DSP Cancer Institute	Setsuko Yamamoto
Senior Director, Modality Research Unit Director, Group II, Modality Research Unit Senior Project Director, Drug Research	Senior Fellow, Oncology Laboratory for Discovery Chemistry & Technology	Hitoshi Ban
Senior Officer, Vaccines	Senior Fellow, Vaccine Project, Drug Research	Akihisa Fukushima
Chairman, President & CEO, Sumitomo Pharma (Suzhou) Co., Ltd.	Managing Director, Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. Managing Director, Sumitomo Pharma Malaysia Sdn. Bhd.	Yoshitaka Koketsu
Managing Director, Sumitomo Pharma Asia Pacific Pte. Ltd. Managing Director, Sumitomo Pharma Malaysia Sdn. Bhd.	Member, Board of Directors, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.	Hiroki Uemukai

Corporate Regulatory Compliance & Quality Assurance (Division)

Position as of April 1, 2022	Current position	Name
Senior Director, Regulatory Compliance & Quality Assurance Management	Senior Director, Technology Research & Development Management	Yuko Morioka

Drug Research (Division)

Position as of April 1, 2022	Current position	Name
Executive Research Director, Drug Research Division	Senior Project Director, Late-phase Drug Research	Takeo Ishiyama

Senior Project Director, DMPK, Drug Research Division	Fellow, Preclinical Research Unit, DMPK	Takao Watanabe
--	--	----------------

Technology Research & Development (Division)

Position as of April 1, 2022	Current position	Name
Senior Director, Technology Research & Development Management	Senior Director, Process Research & Development Laboratories	Mikio Sasaki
Senior Director, Process Research & Development Laboratories	Director, Medicinal Chemistry Group III, Chemistry Research Unit	Nobuhisa Fukuda

Sales & Marketing (Division)

Position as of April 1, 2022	Current position	Name
Deputy Executive Director, Sales & Marketing Division Senior Director, CNS Sales Department	Senior Director, Osaka Branch	Ichiro Takahashi
Deputy Executive Director, Sales & Marketing Division Senior Director, Tokyo Branch	Senior Director, Human Resources	Koji Yamazaki
Senior Alliance Officer	Alliance Officer, Sales & Marketing Management	Hiroko Yuasa
Senior Director, Rare Diseases Office	Director, Product Group III, Product Marketing	Daisuke Ishigami
Senior Director, CNS Product Marketing	Psychiatry Area Marketing Officer, CNS Product Marketing	Masashi Kimura
Senior Director, Personnel Development	Senior Director, Kobe Branch	Tomoko Nakagawa
Senior Director, Sapporo Branch	Director, Human Resources Group, Human Resources	Toshinori Kanata
Senior Director, Tohoku Branch	Senior Director, Sapporo Branch	Katsuhiko Nishida
Senior Director, Kita-Kanto- Koshinetsu Branch	Senior Director, Personnel Development	Satsuki Otani
Senior Director, Keiji-Hokuriku Branch	Senior Director, Kita-Kanto- Koshinetsu Branch	Takafumi Shimizu
Senior Director, Osaka Branch	Senior Director, Kyushu Branch	Hidekatsu Kuroda

Senior Director, Kyushu Branch	Senior Director, Tohoku Branch	Manabu Tatsukawa
--------------------------------	--------------------------------	------------------

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)